(Q33376711)

26 July 2017

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma (English)

1 reference

26 July 2017

0 references

1 reference

Shuji Ozaki

1

1 reference

26 July 2017

Osamu Tanaka

2

1 reference

26 July 2017

Shiro Fujii

3

1 reference

26 July 2017

Yuri Shigekiyo

4

1 reference

26 July 2017

Hirokazu Miki

5

1 reference

26 July 2017

Masahito Choraku

6

1 reference

26 July 2017

Kumiko Kagawa

7

1 reference

26 July 2017

Jin Asano

8

1 reference

26 July 2017

Kyoko Takeuchi

9

1 reference

26 July 2017

Ken-ichi Kitazoe

10

1 reference

26 July 2017

Toshihiro Hashimoto

11

1 reference

26 July 2017

Masahiro Abe

12

1 reference

26 July 2017

Toshio Matsumoto

13

1 reference

26 July 2017

1 August 2007

1 reference

International Journal of Hematology

26 July 2017

1 reference

26 July 2017

86

1 reference

26 July 2017

2

1 reference

26 July 2017

180-185

1 reference

https://scigraph.springernature.com/pub.10.1532/ijh97.07030

26 July 2017

0 references

cites work

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

1 reference

12 December 2020

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

12 December 2020

International staging system for multiple myeloma

1 reference

12 December 2020

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

12 December 2020

Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients

1 reference

12 December 2020

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clin

1 reference

12 December 2020

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

12 December 2020

1 reference

12 December 2020

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

12 December 2020

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

12 December 2020

Severe pulmonary complication after bortezomib treatment for multiple myeloma

1 reference

12 December 2020

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

The proteasome: a suitable antineoplastic target

1 reference

12 December 2020

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

1 reference

12 December 2020

Treatment of multiple myeloma

1 reference

12 December 2020

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

12 December 2020

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

12 December 2020

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

1 reference

12 December 2020

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

12 December 2020

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

12 December 2020

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

1 reference

12 December 2020

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

12 December 2020

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

12 December 2020

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

1 reference

12 December 2020

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1 reference

12 December 2020

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

12 December 2020

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

1 reference

12 December 2020

International uniform response criteria for multiple myeloma.

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

12 December 2020

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

1 reference

12 December 2020

Pathogenesis of myeloma bone disease

1 reference

12 December 2020

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions

1 reference

12 December 2020

Identifiers

DOI

10.1532/IJH97.07030

1 reference

Dimensions Publication ID

26 July 2017

1046239132

0 references

Fatcat ID

release_t3arnc6unvcoddr7ri2trtuwwa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t3arnc6unvcoddr7ri2trtuwwa

24 November 2022

mapped directly with Wikidata item

1 reference